Posted by Michael Wonder on 20 Jan 2021
Amryt’s Myalepta scores NICE backing for rare lipid disorder
20 January 2021 - NICE has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.
Myalepta has been recommended for the treatment of the rare lipid disorder lipodystrophy, which is characterised by an abnormal distribution of fat in the body.
